About Leucine-rich repeat-containing protein 52
Leucine-rich repeat-containing protein 52 (LRRC52) is a protein
from Homo sapiens identified by UniProt accession
Q8N7C0, 313 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 52 |
| UniProt accession | Q8N7C0 |
| Gene | LRRC52 |
| Organism | Homo sapiens |
| Length | 313 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- body height · score 0.35
- adolescent idiopathic scoliosis · score 0.27
- granulocyte count · score 0.10
- azoospermia · score 0.06
- male infertility with teratozoospermia due to single gene mutation · score 0.06
- Male infertility with spermatogenesis disorder due to single gene mutation · score 0.05
- spermatogenic failure 3 · score 0.05
- spermatogenic failure 55 · score 0.05
- spermatogenic failure 7 · score 0.05
- spermatogenic failure 29 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N7C0-F1 | alphafold | PREDICTED | 86.96 | — |
Amino-acid sequence (313 residues)
MSLASGPGPG WLLFSFGMGL VSGSKCPNNC LCQAQEVICT GKQLTEYPLD IPLNTRRLFL NENRITSLPA MHLGLLSDLV YLDCQNNRIR EVMDYTFIGV FKLIYLDLSS NNLTSISPFT FSVLSNLVQL NIANNPHLLS LHKFTFANTT SLRYLDLRNT GLQTLDSAAL YHLTTLETLF LSGNPWKCNC SFLDFAIFLI VFHMDPSDDL NATCVEPTEL TGWPITRVGN PLRYMCITHL DHKDYIFLLL IGFCIFAAGT VAAWLTGVCA VLYQNTRHKS SEEDEDEAGT RVEVSRRIFQ TQTSSVQEFP QLI
Explore Leucine-rich repeat-containing protein 52 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets